Key Takeaways
- • MaxQ Medical closed a $31.5 million Series A financing led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures, with participation from existing investor Hillside Capital.
- • The company is developing an automated, urethra-preserving ultrasound imaging and therapy system for prostate care designed to deliver diagnosis and treatment in a single outpatient procedure.
- • Series A capital will fund team expansion and advancement of the company's clinical program, with the MaxQ System currently in investigational status and not yet available for commercial use in the United States.
- • The platform targets benign prostatic hyperplasia (BPH) initially, with planned expansion into prostate cancer focal therapy and prostate diagnostics.
Summary
MaxQ Medical, a Sunnyvale-based health-technology company, announced the closing of a $31.5 million Series A financing round. The raise was led by three institutional investors—Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures—alongside continued participation from existing backer Hillside Capital.
The company is developing a fully automated transurethral imaging and therapy platform designed to address gaps in prostate care delivery. The MaxQ System combines real-time ultrasound visualization with targeted therapy capabilities, enabling urologists to deliver complete diagnosis and treatment in a single outpatient procedure while preserving the urethra. This approach represents a shift from traditional multi-step therapeutic models that often require multiple visits or separate diagnostic and treatment phases.
MaxQ Medical's initial clinical focus centers on benign prostatic hyperplasia (BPH), a prevalent condition affecting aging male populations. The company has indicated plans to expand the platform's application into prostate cancer focal therapy and diagnostic applications, positioning the technology across a broader portion of the prostate care continuum.
The company will deploy Series A proceeds primarily toward two strategic objectives: scaling its workforce and accelerating clinical development programs. The MaxQ System remains investigational and has not yet received regulatory clearance for commercial deployment in the United States market, indicating the capital raise is intended to support ongoing clinical validation and regulatory pathways rather than immediate commercialization.
The company is developing a fully automated transurethral imaging and therapy platform designed to address gaps in prostate care delivery. The MaxQ System combines real-time ultrasound visualization with targeted therapy capabilities, enabling urologists to deliver complete diagnosis and treatment in a single outpatient procedure while preserving the urethra. This approach represents a shift from traditional multi-step therapeutic models that often require multiple visits or separate diagnostic and treatment phases.
MaxQ Medical's initial clinical focus centers on benign prostatic hyperplasia (BPH), a prevalent condition affecting aging male populations. The company has indicated plans to expand the platform's application into prostate cancer focal therapy and diagnostic applications, positioning the technology across a broader portion of the prostate care continuum.
The company will deploy Series A proceeds primarily toward two strategic objectives: scaling its workforce and accelerating clinical development programs. The MaxQ System remains investigational and has not yet received regulatory clearance for commercial deployment in the United States market, indicating the capital raise is intended to support ongoing clinical validation and regulatory pathways rather than immediate commercialization.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.